Castle Biosciences, Inc. (CSTL) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

CSTL — Fair Value Analysis

Castle Biosciences, Inc.

Current: $29.95Overvalued

Fair Value Range

Bear Case (25th pct.)

$-1.74

-105.8% vs price

Base Case (Median)

$0.14

-99.5% vs price

Bull Case (75th pct.)

$2.03

-93.2% vs price

$-1.74$0.14$2.03

◇ = Current price | |Bear |Base | Bull

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$-3.63	-112.1%	High (40%)
EV/EBITDA	$3.91	-86.9%	Medium (20%)

Interpretation

Based on 2 out of 8 methods, CSTL appears overvalued at the current price of $29.95. The base case fair value of $0.14 implies 99.5% downside.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.